Antibody Patents: Level Up Your IP Strategy with Genus Claims The Amgen v. Sanofi case was a game-changer. Now, protecting a "genus" of similar antibodies is vital for strong IP. Great article by Ulrich Storz from Michalski · Hüttermann & Partner mbB What's the difference? • Old way (epitope-paratope): Patenting based on how the antibody binds. • New way (genus): Patenting based on the antibody's structure and its allowed variations. AI-powered tools help you build this genus with MAbSilico: • MAbTope: Predicts the antibody's binding site (paratope) computationally. • MAbMature: Identifies allowed variations in the antibody's sequence. This means: • Stronger IP: Broader protection for your antibody. • Faster process: Speeds up patent filing. • Cost savings: Reduces expensive lab work. #antibodies #patents #AI #MAbSilico #drugdiscovery #drugdesign #biotech
MAbSilico
Biotechnologie
The only TechBio providing computationally designed antibodies through AI with biological validations associated
À propos
MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery. We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies. While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation. Using NLP technologies we gather information about antibodies and their target in different databases to ensure competitive landscape analysis and the freedom to operate of the computationally designed antibodies candidates.
- Site web
-
http://www.mabsilico.com
Lien externe pour MAbSilico
- Secteur
- Biotechnologie
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Tours
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2017
- Domaines
- Biotechnology, Therapeutic antibody, Antibody, Protein interaction, Epitope mapping, AI, Computation, HPC , in silico, Antibody design et Protein design
Lieux
-
Principal
Tours, FR
-
75 Paris, Ile de france, FR
Employés chez MAbSilico
Nouvelles
-
🔬 Explore the MAbSilico process! From epitope-specific design to optimal manufacturability, we're revolutionizing antibody discovery. Unlock the secrets of our 21-day lead candidate design. 🌐 mabsilico.com #Biotech #Pharma #InSilico
-
-
MAbSilico's technology delivers computational antibody drug design in just 21 days, integrating multi-parameter specifications. Join our 16 ongoing partnering programs and experience the power of our cutting-edge solutions. 🌐 mabsilico.com #Antibody #AI #ML #DrugDesign #DrugDiscovery #Biotech
-
-
🌐 Discover our growing collection of use cases! From scaffold proteins to peptides, our technologies are driving new breakthroughs in biologics. Stay tuned for upcoming case studies and success stories. 🌐 mabsilico.com #DrugDiscovery #Biotech #Pharma #InSilico
-
-
At MAbSilico, we deeply value the dedication of healthcare workers. That's why we're committed to equipping them with cutting-edge computational solutions to develop next-generation antibody drugs that save lives and improve patient outcomes. Together, we're transforming the future of healthcare. 🌐 mabsilico.com #Antibody #AI #ML #DrugDesign #DrugDiscovery
-
-
With a unique database of 70 million sequences, MAbSilico uses computational design to identify alternative sequences and optimize antibody replacement. Discover how we're revolutionizing antibody discovery: 🌐 mabsilico.com #Antibody #AI #ML #DrugDesign #DrugDiscovery
-
-
We are creating a cutting-edge software suite that integrates patented algorithms and databases, backed by 20 years of proven research. Our AI- and machine learning-powered tools streamline two critical steps in early-stage antibody development: lead identification and lead characterization. 🌐 mabsilico.com #Antibody #AI #ML #DrugDiscovery #Biotech
-
-
With unmatched expertise in AI and antibody-based discovery, we've created a groundbreaking in silico platform for Antibody Discovery and Design. 🌐 mabsilico.com #Antibody #AI #ML #DrugDesign
-
-
We're not your typical biotech company. 🔬 Our antibody epitope-driven design technology is transforming the future of healthcare! Learn more about our innovative approach: 🌐 mabsilico.com #DrugDiscovery #BioTech #Pharma #InSilico
-
-
🚀 NAYA Biosciences and MAbSilico Team Up to Develop Next-Generation PD-1 x VEGF Antibody for Cancer 🚀 Exciting news to start the new year! MAbSilico is partnering with NAYA Biosciences (NASDAQ: NAYA) to design a bifunctional #antibody targeting PD-1 x VEGF. The candidate NY-500 is for hepatocellular carcinoma (HCC) and other solid tumors. And guess what? We've partnered with them to leverage our AI-powered antibody design expertise to make NY-500 a best-in-class therapy! 💪 Why is this a big deal? - Synergistic Targeting: NY-500 simultaneously targets PD-1 and VEGF, potentially enhancing anti-tumor immune response and disrupting tumor blood vessel formation. - AI-Powered Optimization: Our collaboration with NAYA leverages our cutting-edge AI to refine NY-500's design for improved efficacy and developability. - Building on Clinical Success: Recent data with another PD-1 x VEGF antibody, ivonescimab, showed promising results, surpassing the current standard of care. We're proud to be part of this innovative collaboration, pushing the boundaries of cancer immunotherapy with AI-driven #antibodydesign. Learn more about NAYA Biosciences and their exciting pipeline: https://lnkd.in/eWWpcAar #AIDrugDiscovery #AntibodyEngineering #ImmunoOncology #CancerTreatment #Partnerships #Innovation
Home | Naya Biosciences
nayabiosciences.com